Corcept Therapeutics faces challenges despite positive analyst outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2024
0mins
Should l Buy CORT?
Source: TipRanks
Corcept Therapeutics Inc (CORT) experienced a significant decline of 8.96%, crossing below its 5-day SMA. This movement occurs amid broader market weakness, with the Nasdaq-100 down 0.48% and the S&P 500 down 0.77%.
Despite the stock's drop, analysts maintain a positive outlook for Corcept, particularly highlighting the potential of its Korlym medication. H.C. Wainwright has reiterated a Buy rating with a price target of $145, citing strong growth prospects and anticipated sales from the upcoming relacorilant launch for Cushing’s syndrome, projected to reach $4.3 billion by 2034. However, Wolfe Research has noted potential near-term hurdles due to patent litigation and antitrust cases, which could impact the stock's performance.
The implications of these developments suggest that while Corcept has promising products in the pipeline, the current market conditions and legal challenges may weigh on investor sentiment, leading to the recent price decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 46.160
Low
50.00
Averages
91.00
High
121.00
Current: 46.160
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their losses before this date to participate in the lawsuit and seek compensation.
- Allegations Overview: The lawsuit alleges that Corcept concealed critical communications with the FDA regarding its lead drug candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025, leading to investor misunderstandings about its approval prospects and impacting shareholder investment decisions.
- Information Discrepancy: The complaint claims that Corcept's management was internally informed of potential failure for relacorilant but externally conveyed optimistic approval expectations, indicating a severe lack of corporate governance and transparency that may have resulted in significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further underscoring the company's accountability and transparency responsibilities.
See More
CORT Investors Urged to Act Before April 21 Deadline in Class Action
- Critical Deadline: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply as Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging prompt submission of loss information to safeguard their rights.
- Allegations Overview: The lawsuit alleges that Corcept concealed significant information regarding its lead drug candidate, relacorilant, as the company publicly emphasized its potential approval while failing to disclose management's private expectations of failure, misleading investors in the process.
- Information Gap: Reed Kathrein, a partner at Hagens Berman, highlighted that the case reveals a
See More
Corcept Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Corcept in the Northern District of California on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025, highlighting significant legal risks and potential liabilities for the company.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the clinical trial results of relacorilant, claiming it provided “powerful support” for FDA approval, while in reality, the FDA raised concerns about the adequacy of clinical evidence, which could undermine the company's credibility and shareholder confidence.
- Stock Price Plunge: Following the announcement of a Complete Response Letter from the FDA on December 31, 2025, Corcept's stock price plummeted from $70.20 to $34.80, a 50.4% drop, reflecting market pessimism regarding the company's future prospects.
- Investor Rights Protection: Investors who suffered losses during the class period are encouraged to contact Bragar Eagel & Squire to understand their legal rights, emphasizing the firm's commitment to protecting investor interests, which may also impact the company's future investment appeal.
See More
Corcept Therapeutics Shareholder Class Action Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that April 21, 2026, is the critical deadline to apply as Lead Plaintiff, urging those who suffered losses to submit their claims promptly.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant facts regarding its lead drug candidate, relacorilant, during communications with the FDA, misleading investors about the drug's approval prospects.
- Market Crash Impact: Following the announcement of receiving a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting severe market disappointment.
- Information Gap Allegations: The complaint asserts that Corcept's management was aware of the clinical data's flaws yet continued to project optimism about approval, creating a significant information gap that may have led to substantial investor losses.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, or risk losing their right to compensation.
- Fee Structure: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that throughout the class period, Corcept misrepresented the strength of clinical trials for its drug relacorilant, claiming robust support for its NDA, while the FDA had raised significant concerns about the clinical evidence, exposing investors to substantial risks.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its extensive experience and success in this field.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: From February 2024 to February 2026, PayPal is accused of overstating its ability to execute business initiatives, misleading investors about its prospects, with a lead plaintiff motion deadline set for April 20, 2026.
- NuScale Power Risk Disclosure: During the period from May to November 2025, NuScale Power allegedly failed to disclose significant risks associated with its nuclear projects, prompting investors to act by April 20, 2026, indicating a loss of confidence in the company's future.
- Corcept Therapeutics Regulatory Issues: Between October 2024 and December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, misleading investors about its business outlook, with a lead plaintiff motion deadline of April 21, 2026.
- Navan, Inc. IPO Controversy: Navan is accused of failing to disclose a 39% increase in sales and marketing expenses during its 2025 IPO, negatively impacting its revenue and market performance, with a lead plaintiff motion deadline of April 24, 2026.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their losses before this date to participate in the lawsuit and seek compensation.
- Allegations Overview: The lawsuit alleges that Corcept concealed critical communications with the FDA regarding its lead drug candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025, leading to investor misunderstandings about its approval prospects and impacting shareholder investment decisions.
- Information Discrepancy: The complaint claims that Corcept's management was internally informed of potential failure for relacorilant but externally conveyed optimistic approval expectations, indicating a severe lack of corporate governance and transparency that may have resulted in significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further underscoring the company's accountability and transparency responsibilities.
See More
CORT Investors Urged to Act Before April 21 Deadline in Class Action
- Critical Deadline: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply as Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging prompt submission of loss information to safeguard their rights.
- Allegations Overview: The lawsuit alleges that Corcept concealed significant information regarding its lead drug candidate, relacorilant, as the company publicly emphasized its potential approval while failing to disclose management's private expectations of failure, misleading investors in the process.
- Information Gap: Reed Kathrein, a partner at Hagens Berman, highlighted that the case reveals a
See More
Corcept Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Corcept in the Northern District of California on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025, highlighting significant legal risks and potential liabilities for the company.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the clinical trial results of relacorilant, claiming it provided “powerful support” for FDA approval, while in reality, the FDA raised concerns about the adequacy of clinical evidence, which could undermine the company's credibility and shareholder confidence.
- Stock Price Plunge: Following the announcement of a Complete Response Letter from the FDA on December 31, 2025, Corcept's stock price plummeted from $70.20 to $34.80, a 50.4% drop, reflecting market pessimism regarding the company's future prospects.
- Investor Rights Protection: Investors who suffered losses during the class period are encouraged to contact Bragar Eagel & Squire to understand their legal rights, emphasizing the firm's commitment to protecting investor interests, which may also impact the company's future investment appeal.
See More
Corcept Therapeutics Shareholder Class Action Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that April 21, 2026, is the critical deadline to apply as Lead Plaintiff, urging those who suffered losses to submit their claims promptly.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant facts regarding its lead drug candidate, relacorilant, during communications with the FDA, misleading investors about the drug's approval prospects.
- Market Crash Impact: Following the announcement of receiving a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting severe market disappointment.
- Information Gap Allegations: The complaint asserts that Corcept's management was aware of the clinical data's flaws yet continued to project optimism about approval, creating a significant information gap that may have led to substantial investor losses.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, or risk losing their right to compensation.
- Fee Structure: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that throughout the class period, Corcept misrepresented the strength of clinical trials for its drug relacorilant, claiming robust support for its NDA, while the FDA had raised significant concerns about the clinical evidence, exposing investors to substantial risks.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its extensive experience and success in this field.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: From February 2024 to February 2026, PayPal is accused of overstating its ability to execute business initiatives, misleading investors about its prospects, with a lead plaintiff motion deadline set for April 20, 2026.
- NuScale Power Risk Disclosure: During the period from May to November 2025, NuScale Power allegedly failed to disclose significant risks associated with its nuclear projects, prompting investors to act by April 20, 2026, indicating a loss of confidence in the company's future.
- Corcept Therapeutics Regulatory Issues: Between October 2024 and December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, misleading investors about its business outlook, with a lead plaintiff motion deadline of April 21, 2026.
- Navan, Inc. IPO Controversy: Navan is accused of failing to disclose a 39% increase in sales and marketing expenses during its 2025 IPO, negatively impacting its revenue and market performance, with a lead plaintiff motion deadline of April 24, 2026.
See More
